Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy

Movement Disorders

Volumn 27, Issue 3, 2012, Pages 421-427

  Boelmans, Kai ^a   Holst, Brigitte ^a   Hackius, Marc ^a   Finsterbusch, Jürgen ^a   Gerloff, Christian ^a   Fiehler, Jens ^a   Münchau, Alexander ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Basal ganglia; Brain iron; Magnetic resonance imaging; Parkinson's disease; Progressive supranuclear palsy

Indexed keywords

IRON;

ADULT; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLOBUS PALLIDUS; HUMAN; INTERRATER RELIABILITY; MALE; MENTAL PATIENT; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; QUANTITATIVE ANALYSIS; RELAXATION TIME; THALAMUS; UNIFIED PARKINSON DISEASE RATING SCALE; WHITE MATTER;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BASAL GANGLIA; BRAIN MAPPING; CASE-CONTROL STUDIES; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; SUPRANUCLEAR PALSY, PROGRESSIVE; THALAMUS;

EID: 84858285794     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24926     Document Type: Article

References (32)

1. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
2. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
3. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8: 270-279.
4. Burn DJ, Lees AJ. Progressive supranuclear palsy: where are we now? Lancet Neurol 2002; 1: 359-369.
5. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5: 75-86.
6. Perez M, Valpuesta JM, de Garcini EM, et al. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. Am J Pathol 1998; 152: 1531-1539.
7. Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 2010; 23: 394-400.
8. Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, Bush AI. Tau protein: relevance to Parkinson's disease. Int J Biochem Cell Biol 2010; 42: 1775-1778.
9. De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008; 31: 151-173.
10. Martin WR. Quantitative estimation of regional brain iron with magnetic resonance imaging. Parkinsonism Relat Disord 2009; 15: S215-S218.
11. Schenck JF. Magnetic resonance imaging of brain iron. J Neurol Sci 2003; 207: 99-102.
12. Ordidge RJ, Gorell JM, Deniau JC, Knight RA, Helpern JA. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 1994; 32: 335-341.
13. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005; 23: 1-25.
14. Langkammer C, Krebs N, Goessler W, et al. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010; 257: 455-462.
15. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
16. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47: 1-9.
17. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129-2170.
18. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
19. An H, Lin W. Quantitative measurements of cerebral blood oxygen saturation using magnetic resonance imaging. J Cereb Blood Flow Metab 2000; 20: 1225-1236.
20. Dexter DT, Jenner P, Schapira AH, Marsden CD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992; 32: S94-S100.
21. Coffey CE, Alston S, Heinz ER, Burger PC. Brain iron in progressive supranuclear palsy: clinical, magnetic resonance imaging, and neuropathological findings. J Neuropsychiatry Clin Neurosci 1989; 1: 400-404.
22. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003; 60: 922-927.
23. Federico F, Simone IL, Lucivero V, et al. Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders. Mov Disord 1997; 12: 903-909.
24. Eckert T, Sailer M, Kaufmann J, et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 2004; 21: 229-235.
25. Graham JM, Paley MN, Grunewald RA, Hoggard N, Griffiths PD. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000; 123: 2423-2431.
26. Schenck JF, Zimmerman EA. High-field magnetic resonance imaging of brain iron: birth of a biomarker? NMR Biomed 2004; 17: 433-445.
27. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem 1958; 3: 41-51.
28. Wallis LI, Paley MN, Graham JM, et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 2008; 28: 1061-1067.
29. Vymazal J, Righini A, Brooks RA, et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 1999; 211: 489-495.
30. Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurology 1993; 43: 697-700.
31. Kosta P, Argyropoulou MI, Markoula S, Konitsiotis S. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J Neurol 2006; 253: 26-32.
32. Lang AE. Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord 2005; 20: S83-S91.